momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (11717)	10/2/2018 2:56:55 PM
From: Miljenko Zuanic	of 12215

RE: VKTX So, it may bail out to 2809. I do believe (and all data so far demonstrate that) THRbeta path is "the best" target, so far, IF one have to control triglycerides and other lipids, by one word "unwanted" excess fat! Long term safety need to be demonstrated clearly, broad "metabolic" use (not NASH only). It may take time for this ( for 2809 and 3916)... I mentioned early, secondary after nash day I would see as weakens...and it is just confirmed.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next